A phase I study of a second-generation immunumodulatory oligonucleotide (HYB2055) in patients with advanced solid malignancies.

被引：0
|
作者：
Hwang, JJ
Martin, R
Fox-Sinclair, ES
Bahrani, A
Sullivan, T
Park, S
Agrawal, S
Burns, T
Waxdal, M
Marshall, JL
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[2] Hybridon Inc, Cambridge, MA USA
[3] FAST Syst Inc, Gaithersburg, MD USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6230S / 6230S
页数：1
相关论文
共 50 条
  • [21] First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies.
    Rodler, E. T.
    Infante, J. R.
    Siu, L. L.
    Smith, D. C.
    Sullivan, D.
    Vlahovic, G.
    Gomez-Navarro, J.
    Liu, G.
    Blakemore, S.
    Thompson, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies.
    Anderson, S
    Dizon, D
    Sabbatini, P
    Dupont, J
    Pezzulli, S
    Massey, A
    Aghajanian, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 151S - 151S
  • [23] A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
    Jones, Suzanne F.
    Siu, Lillian L.
    Bendell, Johanna C.
    Cleary, James M.
    Razak, Albiruni R. A.
    Infante, Jeffrey R.
    Pandya, Shuchi S.
    Bedard, Philippe L.
    Pierce, Kristen J.
    Houk, Brett
    Roberts, W. Gregory
    Shreeve, S. Martin
    Shapiro, Geoffrey I.
    [J]. INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1100 - 1107
  • [24] A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
    Suzanne F. Jones
    Lillian L. Siu
    Johanna C. Bendell
    James M. Cleary
    Albiruni R. A. Razak
    Jeffrey R. Infante
    Shuchi S. Pandya
    Philippe L. Bedard
    Kristen J. Pierce
    Brett Houk
    W. Gregory Roberts
    S. Martin Shreeve
    Geoffrey I. Shapiro
    [J]. Investigational New Drugs, 2015, 33 : 1100 - 1107
  • [25] Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies.
    Springett, GM
    Takimoto, C
    McNamara, M
    Doroshow, JH
    Syed, S
    Eastham, E
    Spriggs, D
    Pezzulli, S
    Michelson, G
    Dupont, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 226S - 226S
  • [26] Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies.
    Von Mehren, M.
    Buck, D.
    Temmer, E.
    Elsayed, Y. A.
    Cohen, R. B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 96S - 96S
  • [27] Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies.
    Gore, L.
    Rivera, E.
    Lavallee, K.
    Holden, S.
    Grolnic, S.
    Cleere, D.
    Moulder, S. L.
    Elsayed, Y. A.
    Eckhardt, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 98S - 98S
  • [28] A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.
    Raj, SKS
    Basche, M
    Gore, L
    Grolnic, S
    Hunt, J
    O'Bryant, CL
    Morrow, M
    Creese, B
    Kangas, M
    Sawlwin, D
    Eckhardt, SG
    Holden, SN
    Holden, SN
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6152S - 6152S
  • [29] Phase I trial of SNS-595 in patients with advanced malignancies.
    Advani, R
    Gordon, M
    Hurwitz, H
    Mendelson, D
    Wakelee, H
    Ebbinghaus, S
    Hoch, U
    Silverman, J
    Havrilla, N
    Adelman, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 159S - 159S
  • [30] A phase I study of carboplatin plus oral topotecan in advanced malignancies.
    Kim, E
    Hochster, H
    Novik, Y
    Chachoua, A
    Speyer, J
    Muggia, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 161S - 161S
12345